H.C. Wainwright raised the firm’s price target on Septerna (SEPN) to $30 from $26 and keeps a Buy rating on the shares. The firm says the SEP-631 clinical data release is on track for a first half of 2026 readout.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SEPN: